Stifel analyst Daniel Arias lowered the firm’s price target on MaxCyte to $11 from $12 and keeps a Buy rating on the shares. The company’s Q3 results was at the top-end of its preannouncement and maintained its guidance, the analyst tells investors. MaxCyte will finish 2023 amidst “big-picture enthusiasm” for the clinical direction of cell therapies, but also some very clear industry-wide challenges that make for lower growth rates and low-visibility when forecasting, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MXCT:
- MaxCyte reports Q3 EPS (11c), consensus (10c)
- MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
- MaxCyte to Participate in Two Upcoming Investor Conferences
- MaxCyte sees FY23 revenue $34M – $36M , consensus $45.07M
- MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance